{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:27:03Z","timestamp":1792686423074,"version":"4.5.0"},"reference-count":146,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Preeclampsia (PE) occurs in approximately 2\u20138% of all pregnancies worldwide and represents one of the primary causes of maternal and fetal morbidity and mortality. Angiogenic growth factors such as placental growth factor (PlGF) and vascular endothelial growth factor (VEGF), along with their tyrosine kinase receptor (Flt-1), play a central role in placental and fetal development. Impaired placentation results in the excessive release of the antiangiogenic soluble fms-like tyrosine kinase-1 (sFlt-1) which is pivotal in the pathogenesis of PE. By binding to and neutralizing angiogenic factors, sFlt-1 disrupts normal angiogenic signaling, creating an imbalance that is often detectable before clinical symptoms of PE appear. Recent studies have highlighted the prognostic potential of the sFlt-1\/PlGf ratio as an early indicator of PE risk, since this ratio has demonstrated value in both confirming and excluding PE in the high-risk population. Its incorporation into routine medical care has the potential to reduce unnecessary hospital admissions, intensive management, and premature deliveries, ultimately lowering healthcare costs. The objective of this review is to highlight the clinical utility of the sFlt-1\/PlGf ratio in the prediction, diagnosis, and management of preeclampsia and to emphasize the cost-effectiveness of implementing sFlt-1\/PlGF ratio measurement in the care of women at risk of developing PE.<\/jats:p>","DOI":"10.3390\/ijms262110431","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T09:16:07Z","timestamp":1761642967000},"page":"10431","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The Role of Angiogenetic Factors in Preeclampsia"],"prefix":"10.3390","volume":"26","author":[{"given":"Angeliki","family":"Papapanagiotou","sequence":"first","affiliation":[{"name":"Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Anastasia","family":"Daskalaki","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, \u201cAlexandra\u201d General Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4332-6409","authenticated-orcid":false,"given":"Antonios N.","family":"Gargalionis","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Biochemistry, \u201cAttikon\u201d University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0798-6262","authenticated-orcid":false,"given":"Angeliki","family":"Margoni","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Domali","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, \u201cAlexandra\u201d General Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7108-211X","authenticated-orcid":false,"given":"George","family":"Daskalakis","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, \u201cAlexandra\u201d General Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5803-4527","authenticated-orcid":false,"given":"Athanasios G.","family":"Papavassiliou","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1152\/physrev.00039.2024","article-title":"The human placenta and its role in reproductive outcomes revisited","volume":"105","author":"Aye","year":"2025","journal-title":"Physiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/j.ajog.2025.01.041","article-title":"Placenta at single-cell resolution in early and late preeclampsia: Insights and clinical implications","volume":"232","author":"Solt","year":"2025","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_3","unstructured":"American College of Obstetricians and Gynecologists, and Task Force on Hypertension in Pregnancy (2013). Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists\u2019 Task Force on Hypertension in Pregnancy. Obstet. Gynecol., 122, 1122\u20131131."},{"key":"ref_4","first-page":"77","article-title":"Hypertensive Disorders of Pregnancy","volume":"39","author":"Khedagi","year":"2021","journal-title":"Cardiol. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S0140-6736(10)60518-1","article-title":"Maternal mortality for 181 countries, 1980\u20132008: A systematic analysis of progress towards Millennium Development Goal 5","volume":"375","author":"Hogan","year":"2010","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0140-6736(10)60279-6","article-title":"Pre-eclampsia","volume":"376","author":"Steegers","year":"2010","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1097\/AOG.0b013e3181a45b25","article-title":"Hypertensive disorders and severe obstetric morbidity in the United States","volume":"113","author":"Kuklina","year":"2009","journal-title":"Obstet. Gynecol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ehjqcco\/qcad065","article-title":"Update on long-term cardiovascular risk after pre-eclampsia: A systematic review and meta-analysis","volume":"10","author":"Inversetti","year":"2024","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"ref_9","unstructured":"(2020). ACOG Practice Bulletin. Obs. Gynecol., 135, e237\u2013e260."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bartsch, E., Medcalf, K.E., Park, A.L., and Ray, J.G. (2016). High Risk of Pre-eclampsia Identification Group. Clinical risk factors for pre-eclampsia determined in early pregnancy: Systematic review and meta-analysis of large cohort studies. BMJ, 353.","DOI":"10.1136\/bmj.i1753"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"American College of Obstetricians and Gynecologists (2018). ACOG Committee Opinion No. 743: Low-dose aspirin use during pregnancy. Obstet. Gynecol., 132, e44\u2013e52.","DOI":"10.1097\/AOG.0000000000002708"},{"key":"ref_12","unstructured":"National Institute for Health and Care Excellence (2023, April 17). Hypertension in Pregnancy: Diagnosis and Management. 25 June 2019. Available online: www.nice.org.uk\/guidance\/ng133."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/HYPERTENSIONAHA.117.10803","article-title":"Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice","volume":"72","author":"Brown","year":"2018","journal-title":"Hypertension"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S1071","DOI":"10.1016\/j.ajog.2020.07.020","article-title":"First trimester preeclampsia screening and prediction","volume":"226","author":"Chaemsaithong","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Meazaw, M.W., Chojenta, C., Muluneh, M.D., and Loxton, D. (2020). Systematic and meta-analysis of factors associated with preeclampsia and eclampsia in sub-Saharan Africa. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0237600"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Stephens, J., Grande, E.D., Roberts, T., Kerr, M., Northcott, C., Johnson, T., Sleep, J., and Ryder, C. (2025). Factors associated with preeclampsia and the hypertensive disorders of pregnancy amongst Indigenous women of Canada, Australia, New Zealand, and the United States: A systematic review and meta-analysis. Curr. Hypertens. Rep., 27.","DOI":"10.1007\/s11906-025-01327-6"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.semnephrol.2017.05.011","article-title":"Preeclampsia: Pathogenesis, Prevention, and Long-Term Complications","volume":"37","author":"Jim","year":"2017","journal-title":"Semin. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/uog.26032","article-title":"Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction","volume":"61","author":"Stepan","year":"2023","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1126\/science.1111726","article-title":"Latest advances in understanding preeclampsia","volume":"308","author":"Redman","year":"2005","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/apha.12106","article-title":"Pathophysiology of hypertension in pre-eclampsia: A lesson in integrative physiology","volume":"208","author":"Palei","year":"2013","journal-title":"Acta Physiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/path.1700930218","article-title":"The physiological response of the vessels of the placental bed to normal pregnancy","volume":"93","author":"Brosens","year":"1967","journal-title":"J. Pathol. Bacteriol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ajog.2010.08.009","article-title":"The \u201cGreat Obstetrical Syndromes\u201d are associated with disorders of deep placentation","volume":"204","author":"Brosens","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1067\/mob.2003.111","article-title":"Longitudinal serum concentrations of placental growth factor: Evidence for abnormal placental angiogenesis in pathologic pregnancies","volume":"188","author":"Taylor","year":"2003","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jss.2008.04.023","article-title":"The role of vascular endothelial growth factor in wound healing","volume":"153","author":"Bao","year":"2009","journal-title":"J. Surg. Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ntellas, P., Mavroeidis, L., Gkoura, S., Gazouli, I., Amylidi, A.L., Papadaki, A., Zarkavelis, G., Mauri, D., Karpathiou, G., and Kolettas, E. (2020). Old Player-New Tricks: Non Angiogenic Effects of the VEGF\/VEGFR Pathway in Cancer. Cancers, 12.","DOI":"10.3390\/cancers12113145"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Koch, S., and Claesson-Welsh, L. (2012). Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb. Perspect. Med., 2.","DOI":"10.1101\/cshperspect.a006502"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/s41388-018-0486-7","article-title":"VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a \u03b21 integrin\/VEGFR autocrine loop","volume":"38","author":"Boudria","year":"2019","journal-title":"Oncogene"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1080\/10739680902997333","article-title":"Molecular diversity of VEGF-A as a regulator of its biological activity","volume":"16","author":"Woolard","year":"2009","journal-title":"Microcirculation"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1172\/JCI119388","article-title":"Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?","volume":"99","author":"Zhou","year":"1997","journal-title":"J. Clin. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1471-0528.1972.tb12922.x","article-title":"On the pathogenesis of placental infarcts in pre-eclampsia","volume":"79","author":"Brosens","year":"1972","journal-title":"J. Obstet. Gynaecol. Br. Commonw."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/0002-9378(75)90522-0","article-title":"The ultrastructure of acute atherosis in hypertensive pregnancy","volume":"123","author":"Robertson","year":"1975","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.placenta.2013.06.308","article-title":"Advanced oxidation protein products enhances soluble Fms-like tyrosine kinase 1 expression in trophoblasts: A possible link between oxidative stress and preeclampsia","volume":"34","author":"Huang","year":"2013","journal-title":"Placenta"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1081\/PRG-120015848","article-title":"Oxidative stress reproduces placental abnormalities of preeclampsia","volume":"21","author":"Vaughan","year":"2002","journal-title":"Hypertens. Pregnancy"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1172\/JCI70431","article-title":"Preeclampsia: A link between trophoblast dysregulation and an antiangiogenic state","volume":"123","author":"Romero","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.placenta.2004.02.011","article-title":"Evidence for the functional activity of hypoxia-inducible transcription factors overexpressed in preeclamptic placentae","volume":"25","author":"Rajakumar","year":"2004","journal-title":"Placenta"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1172\/JCI8316","article-title":"Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3)","volume":"105","author":"Caniggia","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/CIRCRESAHA.118.313276","article-title":"Preeclampsia: Pathophysiology, Challenges, and Perspectives","volume":"124","author":"Rana","year":"2019","journal-title":"Circ. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14767050701830480","article-title":"A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate","volume":"21","author":"Romero","year":"2008","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1161\/CIRCULATIONAHA.109.853127","article-title":"Preeclampsia, a disease of the maternal endothelium: The role of antiangiogenic factors and implications for later cardiovascular disease","volume":"123","author":"Powe","year":"2011","journal-title":"Circulation"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1161\/01.RES.0000147365.86159.f5","article-title":"Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia","volume":"95","author":"Ahmad","year":"2004","journal-title":"Circ. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.plefa.2003.04.010","article-title":"Eicosanoids in preeclampsia","volume":"70","author":"Walsh","year":"2004","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bcp.2015.04.012","article-title":"Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia","volume":"95","author":"Shah","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.placenta.2024.10.011","article-title":"Endothelin-1 potentiated constriction in preeclampsia placental veins: Role of ETAR\/ETBR\/CaV1.2\/CALD","volume":"158","author":"Su","year":"2024","journal-title":"Placenta"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Zolfaghari, M.A., Arefnezhad, R., Parhizkar, F., Hejazi, M.S., MotavalliKhiav, F., Mahmoodpoor, A., and Yousefi, M. (2021). T lymphocytes and preeclampsia: The potential role of T-cell subsets and related MicroRNAs in the pathogenesis of preeclampsia. Am. J. Reprod. Immunol., 86.","DOI":"10.1111\/aji.13475"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Aneman, I., Pienaar, D., Suvakov, S., Simic, T.P., Garovic, V.D., and McClements, L. (2020). Mechanisms of Key Innate Immune Cells in Early- and Late-Onset Preeclampsia. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01864"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Regal, J.F., Burwick, R.M., and Fleming, S.D. (2017). The Complement System and Preeclampsia. Curr. Hypertens. Rep., 19.","DOI":"10.1007\/s11906-017-0784-4"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41581-019-0119-6","article-title":"Pre-Eclampsia: Pathogenesis, Novel Diagnostics and Therapies","volume":"15","author":"Phipps","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Youssef, L., Miranda, J., Blasco, M., Paules, C., Crovetto, F., Palomo, M., Torramade-Moix, S., Garc\u00eda-Calder\u00f3, H., Tura-Ceide, O., and Dantas, A.P. (2021). Complement and Coagulation Cascades Activation Is the Main Pathophysiological Pathway in Early-Onset Severe Preeclampsia Revealed by Maternal Proteomics. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-82733-z"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.cca.2011.07.030","article-title":"ADAMTS13, FVIII, von Willebrand Factor, ABO Blood Group Assessment in Preeclampsia","volume":"412","author":"Alpoim","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Venou, T.M., Vetsiou, E., Varelas, C., Daniilidis, A., Psarras, K., Koravou, E.E., Koutra, M., Touloumenidou, T., Tsolakidis, V., and Papalexandri, A. (2024). Increased Complement Activation and Decreased ADAMTS13 Activity Are Associated with Genetic Susceptibility in Patients with Preeclampsia\/HELLP Syndrome Compared to Healthy Pregnancies: An Observational Case-Controlled Study. J. Pers. Med., 14.","DOI":"10.3390\/jpm14040387"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1R","DOI":"10.1203\/01.PDR.0000159567.85157.B7","article-title":"Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia","volume":"57","author":"Maynard","year":"2005","journal-title":"Pediatr. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3109\/14767058.2013.766694","article-title":"Placental growth factor (PlGF): A key to optimizing fetal growth","volume":"26","author":"Vrachnis","year":"2013","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(05)17987-2","article-title":"Pre-eclampsia","volume":"365","author":"Sibai","year":"2005","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1291\/hypres.28.727","article-title":"Establishing reference values for both total soluble Fms-like tyrosine kinase 1 and free placental growth factor in pregnant women","volume":"28","author":"Hirashima","year":"2005","journal-title":"Hypertens. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/micc.12093","article-title":"Regulation of placental angiogenesis","volume":"21","author":"Chen","year":"2014","journal-title":"Microcirculation"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.placenta.2003.10.010","article-title":"Aspects of Human Fetoplacental Vasculogenesis and Angiogenesis","volume":"25","author":"Mayhew","year":"2004","journal-title":"Placenta"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Zhao, H., Wong, R.J., and Stevenson, D.K. (2021). The Impact of Hypoxia in Early Pregnancy on Placental Cells. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22189675"},{"key":"ref_60","first-page":"981","article-title":"The potential value of diagnostic and predictive serum biomarkers for preeclampsia","volume":"62","author":"Boldeanu","year":"2021","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Basak, T., and Ain, R. (2022). Molecular regulation of trophoblast stem cell self-renewal and giant cell differentiation by the Hippo components YAP and LATS1. Stem Cell Res. Ther., 13.","DOI":"10.1186\/s13287-022-02844-w"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3858\/emm.2012.44.1.025","article-title":"The discovery of placenta growth factor and its biological activity","volume":"44","year":"2012","journal-title":"Exp. Mol. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/uog.14811","article-title":"Serum placental growth factor in the three trimesters of pregnancy: Effects of maternal characteristics and medical history","volume":"45","author":"Tsiakkas","year":"2015","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"Levine","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1161\/CIRCULATIONAHA.113.003215","article-title":"Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: A prospective multicenter study","volume":"128","author":"Chappell","year":"2013","journal-title":"Circulation"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Tomkiewicz, J., and Darmochwa\u0142-Kolarz, D. (2024). A Biomarkers for Early Prediction and Management of Preeclampsia: A Comprehensive Review. Med. Sci. Monit., 30.","DOI":"10.12659\/MSM.944104"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"KaradzovOrlic, N., and Joksi\u0107, I. (2025). Preeclampsia pathogenesis and prediction\u2014Where are we now: The focus on the role of galectins and miRNAs. Hypertens. Pregnancy, 44.","DOI":"10.1080\/10641955.2025.2470626"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2147\/IJWH.S368454","article-title":"Perspectives on the Use of Placental Growth Factor (PlGF) in the Prediction and Diagnosis of Pre-Eclampsia: Recent Insights and Future Steps","volume":"15","author":"Creswell","year":"2023","journal-title":"Int. J. Womens Health"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/HYPERTENSIONAHA.118.12300","article-title":"EGFR (Epidermal Growth Factor Receptor) Signaling and the Mitochondria Regulate sFlt-1 (Soluble FMS-Like Tyrosine Kinase-1) Secretion","volume":"73","author":"Hastie","year":"2019","journal-title":"Hypertension"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/01.AOG.0000147599.47713.5d","article-title":"World Health Organization systematic review of screening tests for preeclampsia","volume":"104","author":"Villar","year":"2004","journal-title":"Obstet. Gynecol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1081\/PRG-120028292","article-title":"Markers for presymptomatic prediction of preeclampsia and intrauterine growth restriction","volume":"23","author":"Tjoa","year":"2004","journal-title":"Hypertens. Pregnancy"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Velegrakis, A., Kouvidi, E., Fragkiadaki, P., and Sifakis, S. (2023). Predictive value of the sFlt 1\/PlGF ratio in women with suspected preeclampsia: An update (Review). Int. J. Mol. Med., 52.","DOI":"10.3892\/ijmm.2023.5292"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/14767050400028816","article-title":"Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia","volume":"17","author":"Chaiworapongsa","year":"2005","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1291\/hypres.30.151","article-title":"Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia","volume":"30","author":"Ohkuchi","year":"2007","journal-title":"Hypertens. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/00016340802253759","article-title":"Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia","volume":"87","author":"Baviera","year":"2008","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_76","first-page":"1663","article-title":"New advances in prediction and surveillance of preeclampsia: Role of machine learning approaches and remote monitoring","volume":"308","author":"Schmidt","year":"2023","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1161\/HYPERTENSIONAHA.113.01787","article-title":"New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1\/placental growth factor ratio as a diagnostic test for preeclampsia","volume":"63","author":"Verlohren","year":"2014","journal-title":"Hypertension"},{"key":"ref_78","first-page":"1159","article-title":"New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis","volume":"52","author":"Prieto","year":"2014","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1414838","article-title":"Predictive Value of the sFlt-1: PlGF Ratio in Women with Suspected Preeclampsia","volume":"374","author":"Zeisler","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1161\/HYPERTENSIONAHA.119.13997","article-title":"Angiogenic marker prognostic models in pregnant women with hypertension","volume":"75","author":"Perry","year":"2020","journal-title":"Hypertension"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Andersen, L.L.T., Helt, A., Sperling, L., and Overgaard, M. (2021). Decision threshold for kryptor sFlt-1\/PlGF ratio in women with suspected preeclampsia: Retrospective study in a routine clinical setting. J. Am. Heart Assoc., 10.","DOI":"10.1161\/JAHA.120.021376"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.preghy.2020.11.010","article-title":"Real life outpatient biomarker use in management of hypertensive pregnancies in third trimester in a low resource Setting: ROBUST study","volume":"23","author":"Soundararajan","year":"2021","journal-title":"Pregnancy Hypertens."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/1471-0528.16383","article-title":"Added prognostic value of longitudinal changes of angiogenic factors in early-onset severe pre-eclampsia: A prospective cohort study","volume":"128","author":"Peguero","year":"2021","journal-title":"BJOG"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1161\/HYPERTENSIONAHA.120.15146","article-title":"Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)\/PlGF (Placental Growth Factor)-Ratio in the Clinical Routine: A Real-World Study","volume":"77","author":"Perschel","year":"2021","journal-title":"Hypertension"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/jog.14815","article-title":"sFlt-1\/PlGF ratio as a predictive and prognostic marker for preeclampsia","volume":"47","author":"Jeon","year":"2021","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"S1037","DOI":"10.1016\/j.ajog.2020.10.028","article-title":"Real-world data on the clinical use of angiogenic factors in pregnancies with placental dysfunction","volume":"226","author":"Czarnowsky","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Hund, M., Allegranza, D., Schoedl, M., Dilba, P., Verhagen-Kamerbeek, W., and Stepan, H. (2014). Multicenter prospective clinical study to evaluate the prediction of short-term outcome in pregnant women with suspected preeclampsia (PROGNOSIS): Study protocol. BMC Pregnancy Childbirth, 14.","DOI":"10.1186\/1471-2393-14-324"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/uog.19178","article-title":"Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: Ruling out pre-eclampsia for up to 4 weeks and value of retesting","volume":"53","author":"Zeisler","year":"2019","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/HYPERTENSIONAHA.119.12760","article-title":"Short-Term Prediction of Adverse Outcomes Using the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)\/PlGF (Placental Growth Factor) Ratio in Asian Women With Suspected Preeclampsia","volume":"74","author":"Bian","year":"2019","journal-title":"Hypertension"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/HYPERTENSIONAHA.119.12739","article-title":"Randomized Interventional Study on Prediction of Preeclampsia\/Eclampsia in Women With Suspected Preeclampsia: INSPIRE","volume":"74","author":"Cerdeira","year":"2019","journal-title":"Hypertension"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Kifle, M.M., Dahal, P., Vatish, M., Cerdeira, A.S., and Ohuma, E.O. (2022). The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: A secondary analysis of data from the INSPIRE trial. BMC Pregnancy Childbirth, 22.","DOI":"10.1186\/s12884-022-04817-6"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/ajo.13549","article-title":"The predictive value of the sFlt-1\/PlGF ratio in suspected preeclampsia in a New Zealand population: A prospective cohort study","volume":"63","author":"Hughes","year":"2023","journal-title":"Aust. N. Z. J. Obstet. Gynaecol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1056\/NEJMoa055352","article-title":"Soluble endoglin and other circulating antiangiogenic factors in preeclampsia","volume":"355","author":"Levine","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1210\/jc.2003-031244","article-title":"First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia","volume":"89","author":"Thadhani","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Verlohren, S., Galindo, A., Schlembach, D., Zeisler, H., Herraiz, I., Moertl, M.G., Pape, J., Dudenhausen, J.W., Denk, B., and Stepan, H. (2010). An automated method for the determination of the sFlt-1\/PIGF ratio in the assessment of preeclampsia. Am. J. Obstet. Gynecol., 202.","DOI":"10.1016\/j.ajog.2009.09.016"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"40.e1","DOI":"10.1016\/j.ajog.2009.07.025","article-title":"Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: A prospective clinical study","volume":"202","author":"Sunderji","year":"2010","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.preghy.2021.12.003","article-title":"Clinical interpretation and implementation of the sFlt-1\/PlGF ratio in the prediction, diagnosis and management of preeclampsia","volume":"27","author":"Verlohren","year":"2022","journal-title":"Pregnancy Hypertens."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ajog.2021.11.1345","article-title":"Ruling out preeclampsia in the next 4 weeks using a soluble fms-like tyrosine kinase 1\/placental growth factor ratio \u226438: Secondary analysis of the Interventional Study on Prediction of Preeclampsia\/Eclampsia in Women With Suspected Preeclampsia","volume":"226","author":"Cerdeira","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Hastie, R., Bergman, L., Walker, S.P., Kaitu\u2019u-Lino, T., Hannan, N.J., Brownfoot, F., Schell, S., Harper, A., Cannon, P., and Cluver, C.A. (2022). Associations between soluble fms-like tyrosine kinase-1 and placental growth factor and disease severity among women with preterm eclampsia and preeclampsia. J. Am. Heart Assoc., 11.","DOI":"10.1161\/JAHA.121.024395"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3233\/CBM-140455","article-title":"Evaluation of Annexin A2 as a novel diagnostic serum biomarker for lung cancer","volume":"15","author":"Yang","year":"2015","journal-title":"Cancer Biomark."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Chen, Y., Huang, L., Zhang, J., and Guo, N. (2025). Serum sFlt-1\/PlGF ratio combined with ANXA2 correlates with adverse pregnancy outcomes in women with suspected preeclampsia. J. Matern. Fetal Neonatal Med., 38.","DOI":"10.1080\/14767058.2025.2506008"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"11514","DOI":"10.1073\/pnas.94.21.11514","article-title":"MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily","volume":"94","author":"Bootcov","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Cruickshank, T., MacDonald, T.M., Walker, S.P., Keenan, E., Dane, K., Middleton, A., Kyritsis, V., Myers, J., Cluver, C., and Hastie, R. (2021). Circulating Growth Differentiation Factor 15 Is Increased Preceding Preeclampsia Diagnosis: Implications as a Disease Biomarker. J. Am. Heart Assoc., 10.","DOI":"10.1161\/JAHA.120.020302"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000151344","article-title":"Longitudinal Determination of Serum Placental Protein 13 during Development of Preeclampsia","volume":"24","author":"Huppertz","year":"2008","journal-title":"Fetal Diagn. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Than, N.G., Balogh, A., Romero, R., K\u00e1rp\u00e1ti, E., Erez, O., Szil\u00e1gyi, A., Kovalszky, I., Sammar, M., Gizurarson, S., and Matk\u00f3, J. (2014). Placental Protein 13 (PP13)\u2014A Placental Immunoregulatory Galectin Protecting Pregnancy. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00348"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Gadde, R., Cd, D., and Sheela, S. (2018). Placental protein 13: An important biological protein in preeclampsia. J. Circ. Biomark., 7.","DOI":"10.1177\/1849454418786159"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Vasilache, I.A., Carauleanu, A., Socolov, D., Matasariu, R., Pavaleanu, I., and Nemescu, D. (2022). Predictive performance of first trimester serum galectin-13\/PP-13 in preeclampsia screening: A systematic review and meta-analysis. Exp. Ther. Med., 23.","DOI":"10.3892\/etm.2022.11297"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/uog.20117","article-title":"Prediction of pre-eclampsia: Review of reviews","volume":"54","author":"Townsend","year":"2019","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1210\/endrev\/bnad017","article-title":"The Pregnancy-Associated Plasma Protein-A (PAPP-A) Story","volume":"44","author":"Conover","year":"2023","journal-title":"Endocr. Rev."},{"key":"ref_110","first-page":"1788","article-title":"Correlation analysis of serum placental growth factor, pregnancy-related plasma protein-A and disease severity in patients with hypertensive disorder in pregnancy","volume":"25","author":"Sun","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Shahsavandi, E., Movahedi, M., Khanjani, S., Shahshahan, Z., Hajihashemi, M., and Farahbod, F. (2023). Evaluation of the relationship between pregnancy-associated plasma protein A (PAPP-A) and pregnancy outcomes. Adv. Biomed. Res., 12.","DOI":"10.4103\/abr.abr_344_21"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Tzanaki, I., Makrigiannakis, A., Lymperopoulou, C., Al-Jazrawi, Z., and Agouridis, A.P. (2025). Pregnancy-associated plasma protein A (PAPP-A) as a first trimester serum biomarker for preeclampsia screening: A systematic review and meta-analysis. J. Matern. Fetal Neonatal Med., 38.","DOI":"10.1080\/14767058.2024.2448502"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.preghy.2016.04.007","article-title":"The utility of first trimester uterine artery Doppler, placental volume and PAPP-A levels alone and in combination to predict preeclampsia","volume":"6","author":"Gedikbasi","year":"2016","journal-title":"Pregnancy Hypertens."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.4103\/jpbs.jpbs_1983_24","article-title":"Prospective Evaluation of Screening Performance of First-Trimester Prediction Models for Preterm Preeclampsia","volume":"17","author":"Zain","year":"2025","journal-title":"J. Pharm. Bioallied Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"598","DOI":"10.12669\/pjms.41.2.9794","article-title":"Predictive value of prenatal screening markers combined with serum placental growth factor in early pregnancy for preeclampsia","volume":"41","author":"Shu","year":"2025","journal-title":"Pak. J. Med. Sci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.placenta.2019.04.005","article-title":"The association between first trimester AFP to PAPP-A ratio and placentally-related adverse pregnancy outcome","volume":"81","author":"Hughes","year":"2019","journal-title":"Placenta"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/EJE-12-0531","article-title":"Umbilica cord levels of sclerostin, placental weight, and birth weight are predictors of total bone mineral content in neonates","volume":"168","author":"Godang","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijgo.12802","article-title":"The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention","volume":"145","author":"Poon","year":"2019","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/uog.18816","article-title":"ASPRE trial: Performance of screening for preterm pre-eclampsia","volume":"50","author":"Rolnik","year":"2017","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/uog.19039","article-title":"Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: Results of SPREE","volume":"51","author":"Tan","year":"2018","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/uog.21869","article-title":"From first-trimester screening to risk stratification of evolving pre-eclampsia in second and third trimesters of pregnancy: Comprehensive approach","volume":"55","author":"Poon","year":"2020","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1161\/HYPERTENSIONAHA.108.127977","article-title":"First-trimester prediction of hypertensive disorders in pregnancy","volume":"53","author":"Poon","year":"2009","journal-title":"Hypertension"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10641955.2019.1682009","article-title":"First trimester screening for preeclampsia\u2014A systematic review","volume":"39","author":"Mosimann","year":"2020","journal-title":"Hypertens. Pregnancy"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/uog.23645","article-title":"Prospective evaluation of first-trimester screening strategy for preterm pre-eclampsia and its clinical applicability in China","volume":"58","author":"Hu","year":"2021","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/HJH.0000000000003366","article-title":"CircRNA_06354 might promote early-onset preeclampsia in humans via hsa-miR-92a-3p\/vascular endothelial growth factor-A","volume":"41","author":"Zhang","year":"2023","journal-title":"J. Hypertens."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Pankiewicz, K., Fija\u0142kowska, A., Issat, T., and Maciejewski, T.M. (2021). Insight into the Key Points of Preeclampsia Pathophysiology: Uterine Artery Remodeling and the Role of MicroRNAs. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063132"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"E836","DOI":"10.1152\/ajpendo.00660.2012","article-title":"Differential miRNA expression profiles between the first and third trimester human placentas","volume":"304","author":"Gu","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Hromadnikova, I., Kotlabova, K., Ivankova, K., and Krofta, L. (2017). First trimester screening of circulating C19MC microRNAs and the evaluation of their potential to predict the onset of preeclampsia and IUGR. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0171756"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Chen, D.B., and Wang, W. (2013). Human placental microRNAs and preeclampsia. Biol. Reprod., 88.","DOI":"10.1095\/biolreprod.113.107805"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Munjas, J., Sopi\u0107, M., Stefanovi\u0107, A., Ko\u0161ir, R., Nini\u0107, A., Joksi\u0107, I., Antoni\u0107, T., Spasojevi\u0107-Kalimanovska, V., and ProsencZmrzljak, U. (2021). Non-Coding RNAs in Preeclampsia-Molecular Mechanisms and Diagnostic Potential. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910652"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.omtn.2021.03.010","article-title":"Serum lncRNAs in early pregnancy as potential biomarkers for the prediction of pregnancy-induced hypertension, including preeclampsia","volume":"24","author":"Dai","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_134","unstructured":"NICE (2021, July 20). PlGF-Based Testing to Help Diagnose Suspected Preeclampsia (Triage PlGF Test, Elecsys Immunoassay sFlt-1\/PlGF Ratio, DELFIA Xpress PlGF 1-2-3 Test, and BRAHMS sFlt-1 Kryptor\/BRAHMS PlGF plus Kryptor PE ratio). Diagnostics Guidance. [DG23]. Available online: https:\/\/www.nice.org.uk\/guidance\/dg23\/."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/eurheartj\/ehy340","article-title":"2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy","volume":"39","author":"Bauersachs","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_136","unstructured":"(2021, November 03). Danish Society for Obstetrics and Gynecology: Danish 2018 National Clinical Guideline for Hypertensive Disorders in Pregnancy and Preeclampsia. Available online: https:\/\/static1.squarespace.com\/static\/5467abcce4b056d72594db79\/t\/5bac84e7652dea0a1b5fb489\/1538032877105\/180924+PE-guideline-final+sandbjerg.pdf."},{"key":"ref_137","unstructured":"German Society of Obstetrics and Gynecology (DGGG), Austrian Society of Obstetrics and Gynecology (OEGGG), and Swiss Society for Obstetric and Gynecology (SGGG) (2019, June 28). Guidelines for Hypertensive Disorders in Pregnancy: Diagnosis and Therapy. Available online: https:\/\/register.awmf.org\/assets\/guidelines\/015-018l_S2k_Diagnostik_Therapie_hypertensiver_Schwangerschaftserkrankungen_2019-07.pdf."},{"key":"ref_138","unstructured":"(2020). Spanish Society of Gynaecology and Obstetrics (SEGO): Practical assistance guide: Hypertensive disorders in pregnancy. Prog. Obstet. Ginecol., 63, 244\u2013272."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/uog.15997","article-title":"sFlt-1\/PlGF ratio test for pre-eclampsia: An economic assessment for the UK","volume":"48","author":"Vatish","year":"2016","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.preghy.2018.04.014","article-title":"Economic evaluation of sFlt-1\/PlGF ratio test in pre-eclampsia prediction and diagnosis in two Brazilian hospitals","volume":"13","author":"Figueira","year":"2018","journal-title":"Pregnancy Hypertens."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.preghy.2021.08.113","article-title":"Enhancing the value of the sFlt-1\/PlGF ratio for the prediction of preeclampsia: Costanalysis from the Belgian healthcare payers\u2019 perspective","volume":"26","author":"Chantraine","year":"2021","journal-title":"Pregnancy Hypertens."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Schlembach, D., Hund, M., Schroer, A., and Wolf, C. (2018). Economic assessment of the use of the sFlt-1\/PlGF ratio test to predict preeclampsia in Germany. BMC Health Serv. Res., 18.","DOI":"10.1186\/s12913-018-3406-1"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1515\/jpm-2017-0288","article-title":"Serum sFlt-1\/PlGF ratio has better diagnostic ability in early- compared to late-onset pre-eclampsia","volume":"47","author":"Chuah","year":"2018","journal-title":"J. Perinat. Med."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Sapantzoglou, I., Rouvali, A., Koutras, A., Chatziioannou, M.I., Prokopakis, I., Fasoulakis, Z., Zachariou, E., Douligeris, A., Mortaki, A., and Perros, P. (2023). sFLT1, PlGF, the sFLT1\/PlGF Ratio and Their Association with Pre-Eclampsia in Twin Pregnancies\u2014A Review of the Literature. Medicina, 59.","DOI":"10.3390\/medicina59071232"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/uog.14799","article-title":"Implementation of the sFlt-1\/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: Implications for clinical practice","volume":"45","author":"Stepan","year":"2015","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3343\/alm.2018.38.2.95","article-title":"Evaluation of sFlt-1\/PlGF Ratio for Predicting and Improving Clinical Management of Pre-eclampsia: Experience in a Specialized Perinatal Care Center","volume":"38","author":"Caillon","year":"2018","journal-title":"Ann. Lab. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/21\/10431\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T09:29:55Z","timestamp":1761643795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/21\/10431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":146,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["ijms262110431"],"URL":"https:\/\/doi.org\/10.3390\/ijms262110431","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]}}}